Simon Dumesnil insider trades: Pasithea Therapeutics (KTTA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Simon reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | KTTA | ↑ Buy | 33,333 | $0.75 | $25K | Direct | Dec 1, 2025 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KTTA insiders
Open-market trades in the last 12 months
About Simon Dumesnil's insider trades
Simon Dumesnil is a director at Pasithea Therapeutics (KTTA). Since Nov 28, 2025, Simon has reported 1 open-market purchase worth $25K and no sales on SEC Form 4. In the last 12 months: 1 buy ($25K).
Their filings also include grants and awards (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KTTA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.